Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637195 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL8881595 | 0.90 | PSMB1 (0.59) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL25182274 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL10985008 | 0.85 | CTSK (0.58) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL10985006 | 0.85 | CTSK (0.58) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL2724462 | 0.84 | CTSK (0.61) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL28225820 | 0.84 | CTSK (0.57) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL14595271 | 0.83 | CTSK (0.64) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL13074183 | 0.83 | CTSK (0.64) | CTSKCTSSCTSLCTSBCTRB1 | |
| SCHEMBL2723504 | 0.83 | CTSK (0.62) | CTSKCTSSCTSLCTSBCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CTSK 3605/4885CTSS 3726/4885CTSL 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.